Mesoblast Limited (ASX:MSB)
1.705
-0.040 (-2.29%)
May 9, 2025, 4:10 PM AEST
Mesoblast Revenue
Mesoblast had revenue of $3.16M USD in the half year ending December 31, 2024, a decrease of -7.77%. This brings the company's revenue in the last twelve months to $5.67M, down -24.07% year-over-year. In the fiscal year ending June 30, 2024, Mesoblast had annual revenue of $5.90M, down -21.32%.
Revenue (ttm)
$5.67M
Revenue Growth
-24.07%
P/S Ratio
243.26
Revenue / Employee
$77.67K
Employees
73
Market Cap
2.23B AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
Jun 30, 2020 | 32.16M | 15.43M | 92.30% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CSL Limited | 24.61B |
Pro Medicus | 184.58M |
Cochlear | 2.31B |
Sonic Healthcare | 9.33B |
Telix Pharmaceuticals | 783.21M |
Ramsay Health Care | 17.12B |
Ansell | 3.00B |
Regis Healthcare | 1.10B |
Mesoblast News
- 4 days ago - Bullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor Trials - Seeking Alpha
- 7 days ago - Mesoblast reports Q3 results - Seeking Alpha
- 9 days ago - Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025 - GlobeNewsWire
- 10 days ago - Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board - GlobeNewsWire
- 22 days ago - Mesoblast (MESO) Expands Ryoncil Coverage to 104 Million Insured Lives | MEOBF Stock News - GuruFocus
- 22 days ago - Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives | MESO Stock News - GuruFocus
- 22 days ago - Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives - GlobeNewsWire
- 5 weeks ago - Mesoblast Allogeneic Cell Therapy Products Are Designated 'U.S. Country of Origin' and Not Subject to U.S. Tariffs - Benzinga